One study has demonstrated that LLY-283 effectively reduces the level of SDMA in SmB proteins, thereby significantly augmenting the inhibitory effects of tyrosine kinase inhibitors (TKIs) like gilteritinib and quizartinib on FLT3-ITD positive MOLM-13 and MV4-11 AML cells. The gene discussed is FLT3; the disease is acute myeloid leukemia.